Randox Laboratories Ltd

United Kingdom

Randox Laboratories Ltd

United Kingdom

Time filter

Source Type

Patent
Randox Laboratories Ltd. | Date: 2017-01-04

Components for enabling immunodection of methoxetamine are described including immunogens, haptens, antibodies and kits.


A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells.


Patent
Randox Laboratories Ltd. | Date: 2017-02-08

The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.


Patent
Randox Laboratories Ltd | Date: 2016-12-20

An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.


Patent
Randox Laboratories Ltd. | Date: 2017-06-14

The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.


Patent
Randox Laboratories Ltd. | Date: 2017-06-28

An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.


Patent
Randox Laboratories Ltd. | Date: 2017-03-13

The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.


Patent
Randox Laboratories Ltd. | Date: 2017-02-15

The present invention describes methods for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, and comparing that level with the level in a normal control sample. The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-29-2016 | Award Amount: 15.57M | Year: 2017

PIXAPP will establish the worlds first open access Photonic Integrated Circuit (PIC) assembly & packaging Pilot Line. It combines a highly-interdisciplinary team of Europes leading industrial & research organisations. PIXAPP provides Europes SMEs with a unique one-stop-shop, enabling them to exploit the breakthrough advantages of PIC technologies. PIXAPP bridges the valley of death, providing SMEs with an easy access route to take R&D results from lab to market, giving them a competitive advantage over global competition. Target markets include communications, healthcare & security, which are of great socio-economic importance to Europe. PIXAPPs manufacturing capabilities can support over 120 users per year, across all stages of manufacturing, from prototyping to medium scale manufacture. PIXAPP bridges missing gaps in the value chain, from assembly & packaging, through to equipment optimisation, test and application demonstration. To achieve these ambitious objectives, PIXAPP will; 1) Combine a group of Europes leading industrial & research organisations in an advanced PIC assembly & packaging Pilot Line facility.2) Develop an innovative Pilot Line operational model that coordinates activities between consortium partners & supports easy user access through a single entry point. 3) Establish packaging standards that provide cost-efficient assembly & packaging solutions, enabling transfer to full-scale industrial manufacture. 4) Create the highly-skilled workforce required to manage & operate these industrial manufacturing facilities.5) Develop a business plan to ensure Pilot Line sustainability & a route to industrial manufacturing. PIXAPP will deliver significant impacts to a wide stakeholder group, highlighting how industrial & research sectors can collaborate to address emerging socio-economic challenges.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 2.12M | Year: 2016

MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients. Because of limitations in current NAFLD treatment therapies, many new efforts focus on exploring non-pharmacologic means for managing the disease and in particular through dietary substances or bioactive phytochemicals in fruits, vegetables, and plants or their products. MAST4HEALTH aims at exploring the effect of Mastiha, a natural product of Greece which was recently shown to possess antioxidant/anti-inflammatory and lipid lowering properties. We designed a multicenter randomized double blind placebo controlled (parallel arm) clinical trial to test the effectiveness of Mastiha supplement as new non-pharmacologic strategy for NAFLD/NASH treatment. MAST4HEALTH will explore gene-diet interactions, more specifically the potential personalized activity of the Mastiha, and correlate genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post-intervention. The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers of the disease. To this end, MAST4HEALTH will train a number of researchers and PhD students in multidisciplinary approaches of this survey. MAST4HEALTH is expected to build and enhance cooperation among partners meanwhile strengthening the interaction between our academic and non-academic sectors

Loading Randox Laboratories Ltd collaborators
Loading Randox Laboratories Ltd collaborators